Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes

Blood blood.2024024965.

https://doi.org/10.1182/blood.2024024965

Published: 2024

Includes: Supplemental data

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Abida Babu, Kathryn Bower, Madiha Siraj, Biwei Cao, Jongphil Kim, Hany Elmariah, Rawan Faramand, Sayeef Mirza, Lia Perez, Asmita Mishra, Farhad Khimani, Jose L. Ochoa-Bayona, Michael Nieder, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan

Blood (2024) 144 (Supplement 1): 4881.

https://doi.org/10.1182/blood-2024-202709

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Somedeb Ball, Najla H. Al Ali, Akriti G. Jain, Moazzam Shahzad, Junmin Whiting, Daniel Lastorino, Zhuoer Xie, Alison R. Walker, Onyee Chan, Eric Padron, Jongphil Kim, Jeffrey E Lancet, David Sallman, Sara M. Tinsley-Vance, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 532.

https://doi.org/10.1182/blood-2024-209273

Published: 2024

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Blood (2024) 144 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2024-206353

Published: 2024

Journal Articles

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2024-202363

Published: 2024

Journal Articles

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Mark B. Meads, Xiaohong Zhao, David R. Noyes, Alexandra Achille, Praneeth Reddy Sudalagunta, Chaomei H. Zhang, Sonila Toska, Jongphil Kim, Samer Sansil, Sean J. Yoder, Ariel Grajales-Cruz, Brandon Blue, Ciara Louise Freeman, Melissa Alsina, Ariosto Siqueira Silva, Xiaofei Song, Rachid Baz, Kenneth H. Shain

Blood (2024) 144 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2024-210232

Published: 2024

Journal Articles

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Ann Nardelli, Jatinder K. Lamba, Jongphil Kim, Jinming Song, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2024-206161

Published: 2024

Journal Articles

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Blood (2024) 144 (Supplement 1): 4871.

https://doi.org/10.1182/blood-2024-208229

Published: 2024

Journal Articles

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Jamila Mammadova, Yanina Pasikhova, Jongphil Kim, Junmin Whiting, Farhad Khimani, Michael D. Jain, Sayeef Mirza, Rawan Faramand, Julio C. Chavez, Bijal D Shah, Olga Klinkova, Aliyah Baluch, Jose L. Ochoa-Bayona, Fabiana Perna, Taiga Nishihori, Nelli Bejanyan, Frederick Locke, Aleksandr Lazaryan

Blood (2024) 144 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2024-201878

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2023-185117

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report

Nelli Bejanyan, Hany Elmariah, Kayla Reid, Bin Yu, Jongphil Kim, Cheryl Cox, Melissa Lowden, Rawan Faramand, Christopher Cubitt, Hien Liu, Justin Boucher, Jose Alejandro Guevara, David A Sallman, Jeffrey Lancet, Joseph A. Pidala, Kumar Karyampudi, Frederick L. Locke, Claudio Anasetti, Marco Davila

Blood (2023) 142 (Supplement 1): 4846.

https://doi.org/10.1182/blood-2023-187058

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2023-184406

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

NARROW

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only